Page 13 - 中国全科医学2022-20

·2442· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

Quality of life in patients with Cushing's disease［J］. Front Endocrinol DOI：10.1210/jc.2009-0806.
（Lausanne），2019，10：862. DOI：10.3389/fendo.2019.00862. ［51］MATHIOUDAKIS N，PENDLETON C，QUINONES-HINOJOSA
［38］VAN DER PAS R，DE BRUIN C，LEEBEEK F W G，et al. The A，et al. ACTH-secreting pituitary adenomas：size does not correlate
hypercoagulable state in Cushing's disease is associated with increased with hormonal activity［J］. Pituitary，2012，15（4）：526-532.
levels of procoagulant factors and impaired fibrinolysis，but is not DOI：10.1007/s11102-011-0362-8.
reversible after short-term biochemical remission induced by medical ［52］FORMENTI A M，MAFFEZZONI F，DOGA M，et al. Growth
therapy［J］. J Clin Endocrinol Metab，2012，97（4）：1303-1310. hormone deficiency in treated acromegaly and active Cushing's
DOI：10.1210/jc.2011-2753. syndrome［J］. Best Pract Res Clin Endocrinol Metab，2017，31（1）：
［39］STUIJVER D J，VAN ZAANE B，FEELDERS R A，et al. Incidence 79-90. DOI：10.1016/j.beem.2017.03.002.
of venous thromboembolism in patients with Cushing's syndrome：a ［53］VOGEL F，BRAUN L T，RUBINSTEIN G，et al. Persisting
multicenter cohort study［J］. J Clin Endocrinol Metab，2011，96 muscle dysfunction in Cushing's syndrome despite biochemical
（11）：3525-3532. DOI：10.1210/jc.2011-1661. remission［J］. J Clin Endocrinol Metab，2020，105（12）：
［40］WAGNER J，LANGLOIS F，LIM D S T，et al. Hypercoagulability dgaa625. DOI：10.1210/clinem/dgaa625.
and risk of venous thromboembolic events in endogenous Cushing's ［54］BRIDE M M，CRESPO I，WEBB S M，et al. Quality of life in
syndrome：a systematic meta-analysis［J］. Front Endocrinol Cushing's syndrome［J］. Best Pract Res Clin Endocrinol Metab，
（Lausanne），2018，9：805. DOI：10.3389/fendo.2018.00805. 2021，35（1）：101505. DOI：10.1016/j.beem.2021.101505.
［41］SUAREZ M G，STACK M，HINOJOSA-AMAYA J M，et al. ［55］STROUD A，DHALIWAL P，ALVARADO R，et al. Outcomes
Hypercoagulability in cushing syndrome，prevalence of thrombotic of pituitary surgery for Cushing's disease：a systematic review and
events：a large，single-center，retrospective study ［J］. J Endocr meta-analysis［J］. Pituitary，2020，23（5）：595-609. DOI：
Soc，2020，4（2）：bvz033. DOI：10.1210/jendso/bvz033. 10.1007/s11102-020-01066-8.
［42］ZILIO M，MAZZAI L，SARTORI M T，et al. A venous ［56］朱蕾蕾，余叶蓉，肖珍，等 . 清晨血皮质醇及促肾上腺皮质激
thromboembolism risk assessment model for patients with Cushing's 素水平用作库欣病经蝶术后缓解标准的临床价值［J］. 四川大
syndrome［J］. Endocrine，2016，52（2）：322-332. DOI： 学学报：医学版，2019，50（2）：260-263. DOI：10.13464/j.
10.1007/s12020-015-0665-z. scuxbyxb.2019.02.024.
［43］TOJA P M，BRANZI G，CIAMBELLOTTI F，et al. Clinical relevance ［57］PETERSENN S，BECKERS A，FERONE D，et al. Therapy of
of cardiac structure and function abnormalities in patients with Cushing's endocrine disease：outcomes in patients with Cushing's disease
syndrome before and after cure［J］. Clin Endocrinol （Oxf），2012， undergoing transsphenoidal surgery：systematic review assessing
76（3）：332-338. DOI：10.1111/j.1365-2265.2011.04206.x. criteria used to define remission and recurrence［J］. Eur J
［44］NTALI G，HAKAMI O，WATTEGAMA M，et al. Mortality of patients Endocrinol，2015，172（6）：R227-239. DOI：10.1530/EJE-
with Cushing's disease［J］. Exp Clin Endocrinol Diabetes，2021，129（3）： 14-0883.
203-207. DOI：10.1055/a-1197-6380. ［58］ALEXANDRAKI K I，KALTSAS G A，ISIDORI A M，et al. Long-
［45］CLAYTON R N，JONES P W，REULEN R C，et al. Mortality in term remission and recurrence rates in Cushing's disease：predictive
patients with Cushing's disease more than 10 years after remission： factors in a single-centre study［J］. Eur J Endocrinol，2013，168
a multicentre，multinational，retrospective cohort study［J］. Lancet （4）：639-648. DOI：10.1530/EJE-12-0921.
Diabetes Endocrinol，2016，4（7）：569-576. DOI：10.1016/ ［59］BROERSEN L H A，BIERMASZ N R，VAN FURTH W R，et al.
S2213-8587（16）30005-5. Endoscopic vs. microscopic transsphenoidal surgery for Cushing's
［46］MAZZIOTTI G，FRARA S，GIUSTINA A. Pituitary diseases and disease：a systematic review and meta-analysis［J］. Pituitary，
bone［J］. Endocr Rev，2018，39（4）：440-488. DOI：10.1210/ 2018，21（5）：524-534. DOI：10.1007/s11102-018-0893-3.
er.2018-00005. ［60］HONEGGER J，GRIMM F. The experience with transsphenoidal
［47］BRAUN L T，FAZEL J，ZOPP S，et al. The effect of biochemical surgery and its importance to outcomes［J］. Pituitary，2018，21（5）：
remission on bone metabolism in Cushing's syndrome：a 2-year follow- 545-555. DOI：10.1007/s11102-018-0904-4.
up study［J］. J Bone Miner Res，2020，35（9）：1711-1717. ［61］PIVONELLO R，DE LEO M，COZZOLINO A，et al. The treatment
DOI：10.1002/jbmr.4033. of Cushing's disease［J］. Endocr Rev，2015，36（4）：385-486.
［48］SCILLITANI A，MAZZIOTTI G，DI SOMMA C，et al. Treatment of DOI：10.1210/er.2013-1048.
skeletal impairment in patients with endogenous hypercortisolism：when ［62］HINOJOSA-AMAYA J M，VARLAMOV E V，MCCARTNEY S，
and how? ［J］. Osteoporos Int，2014，25（2）：441-446. DOI： et al. Hypercortisolemia recurrence in Cushing's disease；a diagnostic
10.1007/s00198-013-2588-y. challenge［J］. Front Endocrinol （Lausanne），2019，10：740.
［49］TZANELA M，KARAVITAKI N，STYLIANIDOU C，et al. DOI：10.3389/fendo.2019.00740.
Assessment of GH reserve before and after successful treatment of adult ［63］ARAUJO-CASTRO M，GARCÍA CANO A，JIMÉNEZ
patients with Cushing's syndrome［J］. Clin Endocrinol （Oxf）， MENDIGUCHÍA L，et al. Diagnostic accuracy of the different
2004，60（3）：309-314. DOI：10.1046/j.1365-2265.2004.01976.x. hormonal tests used for the diagnosis of autonomous cortisol
［50］WEBB S M，MO D J，LAMBERTS S W J，et al. Metabolic， secretion［J］. Sci Rep，2021，11（1）：20539. DOI：10.1038/
cardiovascular，and cerebrovascular outcomes in growth hormone- s41598-021-00011-4.
deficient subjects with previous Cushing's disease or non-functioning pituitary （收稿日期：2022-02-15；修回日期：2022-03-20）
adenoma［J］. J Clin Endocrinol Metab，2010，95（2）：630-638. （本文编辑：赵跃翠）